Monitor next MGC026 data update expected mid-2027 and enrollment progress in SCCHN monotherapy cohort and lorigerlimab CCGC cohort by YE2026. The company's cash runway through 2028 reduces near-term financing risk.
Drugs in focus
MGNX drug pipeline →lorigerlimab
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- Unknown — the drug is in Phase 2 with no registrational trial announced. If the lower-dose LINNET data in H1 2027 is compelling enough to support a registrational path, a potential BLA filing would likely be at least 2-3 years away.
- Next catalyst
- None dated
What to watchThe next catalyst is updated LINNET results at a lower 3 mg/kg Q3W dose, expected in H1 2027, positive data could de-risk the safety profile and support registrational discussions, while further safety issues or weak efficacy would likely impair the asset's value. Meanwhile, watch for partnership/licensing interest in lorigerlimab or the broader pipeline (MGC026), and monitor the stock's elevated ~11% short interest (~10.9 days to cover) which could amplify moves on binary events.
Price Chart
How similar events traded
Executive Summary
MacroGenics posted a corporate presentation on its website with updated clinical data for its B7-H3 ADC MGC026, showing a 27% best overall response rate in heavily pretreated SCCHN patients with no discontinuations due to TRAEs. The company also reported $288M in cash as of September 30, 2026, with cash runway through 2028, and highlighted progress across its pipeline including MGC028, MGC030, and lorigerlimab.
Key Facts
- MGC026 showed 27% best overall response rate (6/22) and 18.2% confirmed ORR (4/22) in SCCHN expansion cohort at 7.5 mg/kg Q3W
- 0% TRAEs leading to discontinuation in SCCHN cohort; no ILD, pneumonitis, or ocular toxicity reported
- $288M cash equivalents and marketable securities as of September 30, 2026
- Cash runway guidance through 2028
- Total revenues for 9 months ended Sep 30, 2026: $58M vs $67M in same period 2025
- R&D expense for 9 months ended Sep 30, 2026: $104M vs $113M in same period 2025
- Next MGC026 update anticipated mid-2027
- Lorigerlimab CCGC cohort: 25% cORR (4/16 evaluable) at 6 mg/kg Q3W; plan to enroll 20 additional patients at 3 mg/kg Q3W by YE2026
Financial Impact
Cash position of $288M provides runway through 2028; revenues declining YoY ($58M vs $67M for 9-month period)
Risk Factors
- Early-stage clinical data (Phase 1) with small sample sizes; data not final and subject to change
- Revenues declining year-over-year; company has no approved products generating revenue
- Competitive B7-H3 ADC landscape with multiple programs in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001125345-26-000077 |
| Document: mgnx-20261113.htm | 0001125345-26-000077 |
| Document: 0001125345-26-000077-index-headers.html | 0001125345-26-000077 |
| Document: 0001125345-26-000077-index.html | 0001125345-26-000077 |
| Document: 0001125345-26-000077.txt | 0001125345-26-000077 |
Track record
21 reports on MGNX
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
- Nov 13, 20263d ago 8-K Neutral 4/10 Viewing Entry $2.31 Now $2.17 −6.06% settles Feb 12
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 Now $2.17 +1.36% settles Feb 11
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers